Back to today’s briefing

Story perspectives

New Drug Combo Boosts Survival in Lung Cancer Trials

5/23/2025

42 6

Summary

Story summary

A groundbreaking phase 3 IMforte trial reveals that the combination of lurbinectedin and atezolizumab dramatically enhances both progression-free and overall survival for patients battling extensive-stage small cell lung cancer, outpacing atezolizumab alone. This pivotal finding, set to be unveiled at the 2025 ASCO Annual Meeting, could redefine treatment approaches for this formidable disease.

1 of 1

Story summary

A groundbreaking phase 3 IMforte trial reveals that the combination of lurbinectedin and atezolizumab dramatically enhances both progression-free and overall survival for patients battling extensive-stage small cell lung cancer, outpacing atezolizumab alone. This pivotal finding, set to be unveiled at the 2025 ASCO Annual Meeting, could redefine treatment approaches for this formidable disease.